New bispecific antibody demonstrates clinical activity in patients with multiple myeloma
Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate, according to results ...
Apr 17, 2023
0
11